Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia using the etest method

Diagnostic Microbiology and Infectious Disease

Volumn 29, Issue 4, 1997, Pages 265-272

  Jones, Ronald N ^a   Salazar, Juan C ^b   Pfaller, Michael A ^a   Doern, Gary V ^a  

^a UNIVERSITY OF IOWA   (United States)

^b FUNDACIÓN VALLE DEL LILI   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; COAGULASE; IMIPENEM; METICILLIN; OXACILLIN; SULPERAZON;

ACINETOBACTER; AGAR GEL DIFFUSION; ANTIBIOTIC RESISTANCE; ARTICLE; CITROBACTER FREUNDII; DRUG POTENCY; ENTEROBACTER; ESCHERICHIA COLI; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PRIORITY JOURNAL; PROTEUS VULGARIS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; SERRATIA; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; AZTREONAM; BETA-LACTAM RESISTANCE; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORINASE; CEPHALOSPORINS; COHORT STUDIES; COLOMBIA; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCUS; SULBACTAM;

EID: 0031424398     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00157-0     Document Type: Article

References (31)

1. Barradell LB, Bryson HM (1994) Cefepime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 47:471-505.
2. Barry AL, Jones RN, The Collaborative Antimicrobial Susceptibility Testing Group (1988) Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination. J Clin Microbiol 26:13-17.
3. Berne TV, Yellin AE, Appelbaum MD (1993) A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. Surg Gynecol Obstet 177(suppl):18-22.
4. Brown DFJ, Brown L (1991) Evaluation of the Etest: A novel method of quantifying antimicrobial activity. J Antimicrob Chemother 27:185-190.
5. Castaneda E, Leal AL, Castillo O, et al. (1997) Distribution of capsular types and antimicrobial susceptibility of invasive isolates of Streptococcus pneumoniae in Colombian children. Microb Drug Resis 3:147-152.
6. Frei R, Jones RN, Pignatari AC, Yamane N, Marco F, Hoban DJ (1994) Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime. Diagn Microbiol Infect Dis 18:167-173.
7. Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP (1996) Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother 40:1289-1293.
8. Gouin F, Papazian L, Martin C (1993) A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care. J Antimicrob Chemother 32(suppl B):205-214.
9. Hancock REW, Bellido F (1992) Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother 29(suppl A):1-6.
10. Hoepelman AIM, Kieft H, Aoun M (1993) International comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother 32(suppl B): 175-186.
11. Jacoby GA, Carreras I (1990) Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 34: 858-862.
12. Jaurequi L, Matzke D, Scott M, Minns P, Hageage G (1993) Cefepime as treatment for osteomyelitis and other bacterial infections. J Antimicrob Chemother 32(suppl B):141-149.
13. Jones RN (1996a) Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med 100(suppl 6A):3S-12S.
14. Jones RN (1996b) The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Diagn Microbiol Infect Dis 25:153-161.
15. Jones RN, Barry AL, Packer RR, Gregory WW, Thornsberry C (1987) The cefoperazone/sulbactam combination: In vitro antimicrobial spectrum, occurrence of synergy and recommendations for dilution susceptibility testing concentrations. J Clin Microbiol 25:1725-1729.
16. Jones RN, Marshall SA (1994) Antimicrobial activity of cefepime tested against Bush group 1 β-lactamase-producing strains resistant to ceftazidime. Diagn Microbiol Infect Dis 19:33-38.
17. Kessler RE, Bies M, Buck RE, Chisholm DR, Pursiano TA, Tsai YH, Misiek M, Price KE, Leitner F (1985) Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum β-lactam antibiotics. Antimicrob Agents Chemother 27:207-216.
18. McCabe R, Chirurgi V, Farkas SA, Haddow A, Heinz G, Greene S (1996) A new therapeutic option for the treatment of pneumonia. Am J Med 100(suppl 6A):60S-67S.
19. Moosdeen F (1997) The evolution of resistance to cephalosporins. Clin Infect Dis 24:487-493.
20. National Committee for Clinical Laboratory Standards (1997a) Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard M2-A6. Wayne, PA: National Committee for Clinical Laboratory Standards.
21. National Committee for Clinical Laboratory Standards (1997b) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards.
22. Philippon A, Arlet G, Lagrange PH (1994) Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 13:17-29.
23. Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D (1996) Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 100(suppl 6A): 83S-89S.
24. Saez-Llorens X, Castano E, Garcia E, Baez C, Ferez M, Tejeira F, McCracken Jr GH (1995) Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 39:937-940.
25. Sanders WE, Tenney JH, Kessler RE (1996) Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 23:454-461.
26. Schrank JH Jr, Kelley JW, McAllister CK (1995) Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia. Clin Infect Dis 20:56-58.
27. Schwartz R, Das Young LR, Ramirez-Ronda C, Frank E (1996) Current and future management of serious skin and skin-structure infections. Am J Med 100(suppl 6A): 90S-95S.
28. Sharifi R, Geckler R, Childs S (1996) Treatment of urinary tract infections: Selecting an appropriate broad-spectrum antibiotic for nosocomial infections. Am J Med 100(suppl 6A):76S-82S.
29. Spangler SK, Jacobs MR, Appelbaum PC (1994) Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother 38:898-900.
30. Thauvin-Eliopoulos C, Tripodi MF, Moellering, Jr. RC, Eliopoulos GM (1997) Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiela pneumoniae. Antimicrob Agents Chemother 41:1053-1057.
31. Thornsberry C, Yee YC (1996) Comparative activity of eight antibiotics against clinical bacterial isolates from the United States: Broth microdilution (MicroScan) and the Etest method. Am J Med 100(suppl 6A):26S-38S.